Ozmosi | Indoximod Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Indoximod

Alternative Names: indoximod, 1-methyl-d-tryptophan, NLG8189, NLG 8189, NLG-8189, D-1MT
Clinical Status: Inactive
Latest Update: 2024-08-30
Latest Update Note: Clinical Trial Update

Product Description

A methylated tryptophan with immune checkpoint inhibitory activity. Indoximod inhibits the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades the essential amino acid tryptophan, and may increase or maintain tryptophan levels important to T cell function. Tryptophan depletion is associated with immunosuppression involving T cell arrest and anergy. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/indoximod)

Mechanisms of Action: IDO1 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Double Point Ventures
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Melanoma

Phase 2: Male Breast Cancer|Prostate Cancer|Melanoma|Breast Cancer|Glioma|Ependymoma|Glioblastoma|Medulloblastoma

Phase 1: Lung Cancer|Breast Cancer|Melanoma|Pancreatic Cancer|Oncology Solid Tumor Unspecified|Kidney Diseases|Ependymoma|Glioma|Brain Cancer|Medulloblastoma|Healthy Volunteers|Non-Small-Cell Lung Cancer|Acute Myeloid Leukemia|Glioblastoma|Gliosarcoma

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05106296

GCC2020

P1

Recruiting

Brain Cancer|Ependymoma|Glioblastoma|Medulloblastoma

2026-08-01

2024-11-27

Primary Endpoints|Treatments

NCT02502708

NLG2105

P1

Completed

Brain Cancer|Glioma|Ependymoma|Gliosarcoma|Glioblastoma|Medulloblastoma

2019-12-12

12%

2024-11-27

Primary Endpoints|Treatments

NCT02835729

NLG2106

P1

Completed

Acute Myeloid Leukemia

2019-10-25

12%

2024-11-27

Primary Endpoints|Treatments

NCT03852446

NLG2111

P1

Completed

Healthy Volunteers

2018-03-05

2019-03-22

Treatments

NCT03372239

NLG2108

P1

Completed

Healthy Volunteers

2018-01-25

60%

2019-03-21

Treatments

NCT02460367

NSCLS

P1

Terminated

Non-Small-Cell Lung Cancer

2017-07-17

50%

2022-04-07

Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT01191216

NCI-2011-02528

P1

Completed

Oncology Solid Tumor Unspecified

2013-08-01

2019-03-19

Treatments

NCT00739609

D-1MT

P1

Terminated

Lung Cancer|Melanoma|Pancreatic Cancer|Breast Cancer

2012-10-01

2019-03-18

Treatments

NCT00567931

NCI-2009-00268

P1

Completed

Kidney Diseases

2012-07-01

2019-03-22

Treatments

NCT04049669

GCC1949

P2

Recruiting

Medulloblastoma|Glioblastoma|Glioma|Ependymoma

2025-10-02

2024-11-27

Primary Endpoints|Treatments

2014-003540-12

2014-003540-12

P2

Terminated

Breast Cancer

2022-05-04

2022-03-13

Treatments

NCT03301636

NLG2107

P2

Terminated

Melanoma

2019-10-21

50%

2020-06-06

NCT01560923

2011LS109

P2

Completed

Prostate Cancer

2018-12-12

2019-05-01

Primary Completion Date|Study Completion Date|Treatments|Trial Status

NCT02073123

NLG2103

P2

Completed

Melanoma

2018-01-17

50%

2020-06-06

Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT01792050

NLG2101

P2

Completed

Breast Cancer

2016-07-01

2019-03-19

Primary Completion Date|Study Completion Date|Treatments|Trial Status

NCT01042535

NCI-8461

P2

Completed

Male Breast Cancer

2014-12-01

2019-03-19

Treatments

2017-003634-93

2017-003634-93

P3

Unknown status

Melanoma

2021-11-28

2022-03-13

Treatments